With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’ 

Antiviral play Atea could soon join this year’s growing class of “mega-IPOs” via an offering to sell 11 million shares at $22-$24 on NASDAQ. At the midpoint, Atea would raise $253 million and be valued at $1.8 billion. 

Last week, Roche (SIX:ROG; OTCQX:RHHBY) paid Atea Pharmaceuticals Inc. $350 million up front for ex-U.S. rights to AT-527, a direct-acting antiviral against SARS-CoV-2 that could become the first oral antiviral to treat COVID-19 patients outside the hospital setting. ...